Motley Fool Asset Management LLC Has $246,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Motley Fool Asset Management LLC decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,870 shares of the company’s stock after selling 168 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Neurocrine Biosciences were worth $246,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NBIX. Tokio Marine Asset Management Co. Ltd. raised its position in Neurocrine Biosciences by 3.6% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,048 shares of the company’s stock worth $402,000 after purchasing an additional 107 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Neurocrine Biosciences in the 4th quarter worth approximately $119,000. Linden Thomas Advisory Services LLC lifted its position in shares of Neurocrine Biosciences by 3.6% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 6,456 shares of the company’s stock worth $851,000 after buying an additional 225 shares during the period. Larson Financial Group LLC boosted its stake in Neurocrine Biosciences by 20,418.2% in the 4th quarter. Larson Financial Group LLC now owns 2,257 shares of the company’s stock valued at $297,000 after buying an additional 2,246 shares in the last quarter. Finally, Jennison Associates LLC grew its position in Neurocrine Biosciences by 10.3% in the fourth quarter. Jennison Associates LLC now owns 451,462 shares of the company’s stock valued at $59,485,000 after acquiring an additional 41,987 shares during the period. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Down 1.3 %

NASDAQ:NBIX opened at $135.99 on Friday. The firm has a market capitalization of $13.53 billion, a price-to-earnings ratio of 56.19 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 1-year low of $89.04 and a 1-year high of $148.37. The business’s 50-day moving average price is $136.63 and its two-hundred day moving average price is $127.85.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. During the same quarter last year, the firm earned $0.88 EPS. Neurocrine Biosciences’s quarterly revenue was up 25.0% compared to the same quarter last year. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.83 earnings per share for the current year.

Insider Activity

In related news, CEO Kevin Charles Gorman sold 2,707 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total transaction of $380,847.83. Following the sale, the chief executive officer now owns 502,188 shares of the company’s stock, valued at approximately $70,652,829.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,707 shares of the stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total value of $380,847.83. Following the completion of the sale, the chief executive officer now directly owns 502,188 shares in the company, valued at $70,652,829.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David W. Boyer sold 456 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total value of $64,733.76. Following the transaction, the insider now owns 4,894 shares in the company, valued at approximately $694,752.24. The disclosure for this sale can be found here. Insiders sold 186,994 shares of company stock valued at $25,806,409 in the last quarter. Company insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NBIX. The Goldman Sachs Group lifted their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $140.00 to $170.00 in a research report on Wednesday. Finally, Citigroup cut their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a research report on Thursday, February 8th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $142.38.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.